Siliq (brodalumab) / AstraZeneca, Bausch Health, LEO Pharma, Kyowa Kirin - LARVOL DELTA

P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa. (PubMed, Br J Dermatol) - "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."

Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis. (PubMed, J Drugs Dermatol) - "This has the potential to dramatically improve the mental and social burdens faced by patients with moderate-to-severe psoriasis. &nbsp."

Journal • Review • Dermatology • Immunology • Psoriasis • IL17A

Comparing the clinical profile with immunohistochemistry in psoriasis treatment with interleukin 17RA inhibitor using survivin as a biomarker (ISDS 2025) - "This study represents the first systematic examination of the clinical and immunohistochemical improvement of psoriasis in patients receiving brodalumab treatment, in comparison to a control group, with a specific emphasis on the survivin biomarker associated with the disease. Our findings underscore the potential of survivin as a significant biomarker in the current landscape of psoriasis research."

Biomarker • Clinical • Dermatology • Immunology • Psoriasis • BIRC5 • IL17A

Impact of Biologic Class on Ocular Outcomes in Psoriasis: Insights from a Multi-Institutional Database Study (ISDS 2025) - "Adults aged 18–89 years with psoriasis who initiated either TNFα inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) or IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) within one year of diagnosis were identified. In this large, multi-institutional analysis, psoriasis patients treated with TNFα inhibitors experienced higher rates of several ocular inflammatory and degenerative conditions compared to those treated with IL-17 inhibitors. These findings highlight the importance of considering ocular comorbidity risk when selecting biologic therapy for psoriasis."

Clinical • Cataract • Conjunctivitis • Dermatology • Dry Eye Disease • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis • Uveitis • IL17A

Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan. (PubMed, Mod Rheumatol) - "ResultsIncluded patients received adalimumab (n = 323), brodalumab (n = 71), certolizumab pegol (n = 162), guselkumab (n = 157), ixekizumab (n = 239), risankizumab (n = 117), secukinumab (n = 250), or ustekinumab (n = 60). ConclusionSwitching and discontinuation were common within 1-year of bDMARD treatment for PsA patients in Japan. Risankizumab demonstrated the lowest rates of switching and/or discontinuation."

Journal • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Predicting human subcutaneous bioavailability of monoclonal antibodies using an open flow microperfusion porcine model. (PubMed, J Control Release) - "This study presents a novel approach combining open flow microperfusion (OFM) technology in a porcine model with physiologically based pharmacokinetic (PBPK) modeling to investigate local mAb-tissue interactions and predict human bioavailability of three commercially available mAbs (alirocumab, brodalumab, secukinumab). Furthermore, tissue biopsies indicated an inverse correlation between local mAb retention and human SC bioavailability. Our integrated approach of OFM technology and OFM-informed PBPK modeling thus offers a robust strategy for predicting human SC bioavailability of mAbs."

Journal • Preclinical

Atractylenolide III Ameliorates Ulcerative Colitis By Targeting IL-17RA to Suppress Macrophage M1 Polarization. (PubMed, J Agric Food Chem) - "The in vivo mechanism was further confirmed using the IL-17RA antagonist Brodalumab, while plasmid transfection experiments provided additional mechanistic insights into cellular models. These findings demonstrate that ATL III exerts its therapeutic effects on UC by directly targeting IL-17RA, thereby suppressing proinflammatory NF-κB and MAPK signaling pathways and attenuating macrophage M1 polarization, ultimately mitigates UC-associated symptoms and intestinal barrier damage."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL17A • IL17RA

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial. (PubMed, J Eur Acad Dermatol Venereol) - "Brodalumab SC 210 mg Q2W administered for 68 weeks showed a long-term benefit to both dermatological and quality of life indices in these patients. It is expected to be used in appropriate patients, considering both safety risks and efficacy benefits."

Clinical • Journal • P3 data • Dermatology • Immunology • Infectious Disease • Otorhinolaryngology • Psoriasis

Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis). (PubMed, Dermatol Pract Concept) - "Our results are in line with the current literature and suggest that patients who have failed therapy with IL-23 or IL-12/23 inhibitors may benefit from switching to brodalumab, which could be considered a good choice for patients who need a rapid resolution of the inflammatory skin condition."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL12A • IL23A

Real-World Costs per Treatment Sequence and per Responder for Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: Evidence From Three Italian Centers (ISPOR-EU 2025) - "Sensitivity analyses varied the second-line agents in Sequences 1 and 2. The base sequence (adalimumab, brodalumab, guselkumab, ixekizumab) resulted in the lowest cumulative cost per patient at the third year (€17,426), compared to €18,184 in sequence 1 (adalimumab, risankizumab, guselkumab, ixekizumab) and €19,087 in sequence 2 (adalimumab, secukinumab, guselkumab, ixekizumab)...In the sensitivity analysis, the base sequence remained the most cost favorable compared to Sequence 1 (tildrakizumab) and Sequence 2 (ustekinumab) in second line. The results indicate that sequencing strategies have a substantial impact on the cost effectiveness of biologic treatments for psoriasis. The results indicate that sequencing strategies have a substantial impact on the cost effectiveness of biologic treatments for psoriasis. The primary objective confirmed brodalumab as the most economically sustainable strategy across the simulations conducted. These findings may support evidence..."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: To compare efficacy and safety of IL-17 inhibitors in the treatment of adults with active radiographic axial spondyloarthritis (r-AxSpA) over a 16-week period using network meta-analysis (NMA). We conducted systematic literature search in PubMed and Embase in November 2024 to retrieve publications with results of randomized controlled trials (RCTs) evaluating efficacy and safety of IL-17 inhibitors (netakimab, secukinumab, ixekizumab, bimekizumab, brodalumab, xeligekimab, vunakizumab) in adults with active r-AxSpA... Netakimab showed the highest relative efficacy among available IL-17 inhibitors used to treat adults with active r-AxSpA over 16-week horizon and demonstrated a favorable safety profile."

Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review (ACR Convergence 2025) - "Biologics included: adalimumab, secukinumab, etanercept, infliximab, ustekinumab, ixekizumab, guselkumab, risankizumab, apremilast, baricitinib, ruxolitinib, brodalumab, dupilumab, and belimumab. This review highlights the expanding role of biologics in the treatment of rheumatologic conditions beyond their primary dermatologic indications. Their interdisciplinary applications present new opportunities for research and clinical practice, underscoring the need for further investigation to optimize their use and broaden their therapeutic scope."

Review • Ankylosing Spondylitis • Dermatology • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Systemic Lupus Erythematosus • IL17A • IL23A

Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis). (PubMed, Clin Exp Dermatol) - "In this multicenter real-life study, bimekizumab provides exploratory evidence on the cumulative clinical benefit of biologics in moderate-to-severe psoriasis. These findings highlight the importance of cumulative endpoints and individualized treatment strategies in daily practice."

Journal • Dermatology • Immunology • Inflammation • Pain • Psoriasis

Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis. (PubMed, Dermatol Ther (Heidelb)) - "Anti-psoriatic biologics were not associated with an increased risk of MACE in psoriasis patients. Given that most included RCTs were of relatively short duration, longer-term studies and post-marketing surveillance are needed to clarify the cardiovascular safety profile of biologic therapies. Further large-scale studies with extended follow-up are warranted."

Journal • Retrospective data • Review • Cardiovascular • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL23A

A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors. (PubMed, Genes (Basel)) - "This GWAS identified novel variants that could be utilized upon validation in larger populations as predictive markers regarding patient response to drugs targeting the IL-17A pathway."

Journal • Dermatology • Immunology • Psoriasis • IL17A • NRG1 • SCN8A • TP63

Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis. (PubMed, J Psoriasis Psoriatic Arthritis) - "Studies evaluating AEs of interest for brodalumab showed no causal link to suicide and no increase in risk of cardiac events or serious infection compared with other biologics. Together, these studies support a consistent safety profile of brodalumab in real-world use."

HEOR • Journal • Real-world evidence • Review • Cardiovascular • CNS Disorders • Depression • Dermatology • Immunology • Infectious Disease • Oncology • Psoriasis • Psychiatry • IL17A • IL17RA

Psychiatric Adverse Effects of Biologic and Novel Systemic Agents for Psoriasis and Inflammatory Bowel Disease: A Case Series and Literature Review. (PubMed, J Acad Consult Liaison Psychiatry) - "Despite improvement in depressive or anxiety symptoms with these agents, psychiatric symptoms may emerge during treatment underscoring the need for careful monitoring. Clinicians should consider individual psychiatric history when selecting immune-modulating therapies for psoriasis and IBD."

Adverse events • Journal • Review • CNS Disorders • Crohn's disease • Depression • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Psoriasis • Psychiatry • Ulcerative Colitis

Spesolimab as treatment option for refractory Acrodermatitis Continua of Hallopeau (EADV 2025) - "Following this, she was treated with various systemic therapies (acitretin, fumaric acid esters, glucocorticoids, methotrexate, cyclosporine), several biologics (ustekinumab, secukinumab, adalimumab, ixekizumab, guselkumab, apremilast, anakinra, infliximab, risankizumab, brodalumab, bimekizumab, tildrakizumab), Janus kinase inhibitors (tofacitinib, upadacitinib), and a combination of both (risankizumab and tofacitinib)...After the second dose, the patient noted signs of effluvium, which were subsequently treated with topical minoxidil... This case highlights the successful application of spesolimab, a targeted IL-36 inhibitor, as a novel treatment option for a patient suffering from severe refractory acrodermatitis continua of Hallopeau (ACH). To the best of our knowledge, this is the first case of treating acrodermatitis continua of Hallopeau (ACH) with subcutaneous spesolimab.The emergence of effluvium as a potential side effect following treatment necessitates careful..."

Cardiovascular • Dermatitis • Dermatology • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Pain • Osteoarthritis • Psoriasis • Pulmonary Arterial Hypertension • Pustular Psoriasis • Rheumatology • Type 2 Diabetes Mellitus

Shared Immunopathologic and Biologic Targets in Comorbid Dermatologic and Gastrointestinal Disease (EADV 2025) - "Biologics included: adalimumab, secukinumab, etanercept, infliximab, ustekinumab, ixekizumab, guselkumab, risankizumab, apremilast, baricitinib, ruxolitinib, brodalumab, dupilumab, and belimumab. This review highlights the expanding role of biologics in the treatment of gastrointestinal conditions beyond their primary dermatologic indications. Their interdisciplinary applications present new opportunities for research and clinical practice, underscoring the need for further investigation to optimize their use and broaden their therapeutic scope."

Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Psoriasis • Rheumatology • Ulcerative Colitis

Molecular profile of interleukin-17RA blockade by brodalumab in Japanese patients with psoriasis: Results from the ESPRIT study. (PubMed, J Dermatol Sci) - "In summary, the transcriptome and the proteome characteristics of Japanese and Western psoriasis patients were similar. Brodalumab rapidly improved skin and serum molecular levels and reduced cardiovascular disease risk factor expression."

Journal • Cardiovascular • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • IL17RA

The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis. (PubMed, Int J Mol Sci) - "This study replicates known genetic associations with biologic response in psoriasis. Variants in IRAK3 and CD84 show potential as stratification biomarkers, although they need confirmation in independent cohorts."

Journal • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL17A

No Change in HbA1c Levels During Treatment with Biologics or Methotrexate in Patients with Psoriasis. (PubMed, Dermatology) - "Treatment of patients with psoriasis with biologics or methotrexate for 1 year does not appear to affect blood glucose levels as measured by HbA1c. This could indicate that the treatments lack antidiabetic properties."

Journal • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Our review shows that, compared to placebo, the biologics infliximab, xeligekimab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis, with high-certainty evidence for bimekizumab and moderate-certainty evidence for infliximab, xeligekimab, ixekizumab, and risankizumab. This network meta-analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice. More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis)...."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Effect of disease duration on effectiveness of biologics in patients with psoriasis: A single-center retrospective study in Japan (EADV 2025) - "Biologic agents included IL-23 inhibitors (risankizumab, guselkumab), IL-17 inhibitors (ixekizumab, secukinumab, brodalumab), and the TNF-α inhibitor (adalimumab). This study suggests that approximately 90% of patients with a disease duration of ≤2 years achieved complete skin clearance within 6M of initiating biologic therapy. In contrast, while comparable percentage of patients with a disease duration >2 years ultimately reached complete clearance skin at 2Y, a longer period was required for some patients to achieve these outcomes."

Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A